If You Liked Part D, You'll Love Universal Coverage
This article was originally published in RPM Report
It’s hard to say for sure how big a boost universal coverage would give to pharmaceutical companies’ bottom lines. But the industry’s most recent experience with expanded coverage in the key Medicare market offers some encouraging benchmarks for what to expect.
You may also be interested in...
While many people were watching the Senate grapple with drug price negotiation authority for CMS, Big Pharma blew past Wall Street's expectations with big first quarter gains. One year into the program, Medicare is definitely paying off. But will the party last?
A Senate Health Committee update hearing on the COVID-19 federal response was noteworthy primarily for demonstrating that FDA Commissioner Stephen Hahn appears to have salvaged the agency’s position as a voice of credibility with a key political constituency – at least for now.
Before taking over the US health department, Alex Azar helped bring landmark litigation challenging the scope of FDA’s regulatory authority under the First Amendment. Now his tenure is ending with a First Amendment defense of the agency.